Option chain shows key data for Fortress Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Fortress Biotech.

Fortress Biotech (NASDAQ:FBIOP) Stock, Option Chain

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACRS

ADMA

FBIOP

GNPX

MRNA

ONTX

ONVO

PDSB

REXN

TTNP

XERS

ZSAN

13 Healthcare Stocks Moving In Wednesday&#39;s Pre-Market Session

12 Biotechnology Stocks Moving In Wednesday&#39;s Pre-Market Session

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Inc

News

Dividends

Press Releases

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Earnings

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Financing

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Fortress Biotech to Participate in October 2024 Investor Conferences

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

ATXI

CKPT

DERM

FBIO

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Fortress Biotech

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeOne Medicines

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Comments

Fortress Biotech

Fortress Biotech (FBIOP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga